HRP20010325A2 - STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR - Google Patents

STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR Download PDF

Info

Publication number
HRP20010325A2
HRP20010325A2 HR20010325A HRP20010325A HRP20010325A2 HR P20010325 A2 HRP20010325 A2 HR P20010325A2 HR 20010325 A HR20010325 A HR 20010325A HR P20010325 A HRP20010325 A HR P20010325A HR P20010325 A2 HRP20010325 A2 HR P20010325A2
Authority
HR
Croatia
Prior art keywords
active substance
pharmaceutical preparation
solid pharmaceutical
stable solid
pravastatin
Prior art date
Application number
HR20010325A
Other languages
English (en)
Croatian (hr)
Inventor
Janez Kerc
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Publication of HRP20010325A2 publication Critical patent/HRP20010325A2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
HR20010325A 1998-12-16 2001-05-07 STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR HRP20010325A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9800309A SI20109A (sl) 1998-12-16 1998-12-16 Stabilna farmacevtska formulacija
PCT/IB1999/001749 WO2000035425A1 (en) 1998-12-16 1999-10-29 STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR

Publications (1)

Publication Number Publication Date
HRP20010325A2 true HRP20010325A2 (en) 2002-06-30

Family

ID=20432372

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010325A HRP20010325A2 (en) 1998-12-16 2001-05-07 STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR

Country Status (25)

Country Link
US (3) US6680341B1 (es)
EP (2) EP1911445A3 (es)
JP (1) JP2002532409A (es)
KR (1) KR100638307B1 (es)
CN (1) CN1198597C (es)
AT (1) ATE380020T1 (es)
AU (1) AU775946B2 (es)
BG (1) BG105559A (es)
CA (1) CA2348988C (es)
CZ (1) CZ302562B6 (es)
DE (1) DE69937691T2 (es)
ES (1) ES2299265T3 (es)
HR (1) HRP20010325A2 (es)
HU (1) HUP0104258A3 (es)
IL (2) IL143759A0 (es)
IS (1) IS5939A (es)
NZ (1) NZ511260A (es)
PL (1) PL347686A1 (es)
RU (1) RU2227019C2 (es)
SI (2) SI20109A (es)
SK (1) SK8092001A3 (es)
TR (1) TR200101235T2 (es)
WO (1) WO2000035425A1 (es)
YU (1) YU35501A (es)
ZA (1) ZA200103802B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP2382970B1 (en) 2000-04-10 2013-01-09 Teva Pharmaceutical Industries, Ltd. Stable Pharmaceutical Compositions Containing 7-Substituted-3,5-Dihydroxyheptanoic Acids or 7-Substituted-3,5-Dihydroxyheptenoic Acids
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
SI1292293T1 (en) * 2000-06-09 2004-06-30 LEK farmacevtska dru�ba d.d. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
AU2000250960A1 (en) 2000-06-09 2001-12-17 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US20050215636A1 (en) * 2000-10-05 2005-09-29 Vilmos Keri Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
BR0208504A (pt) * 2001-03-27 2004-03-09 Ranbaxy Lab Ltd Composição farmacêutica estável de pravastatina
GB0111077D0 (en) 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
US7642286B2 (en) * 2001-06-21 2010-01-05 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions containing pravastatin
JP2003055217A (ja) * 2001-08-10 2003-02-26 Taiyo Yakuhin Kogyo Kk 医薬組成物
JP2005519052A (ja) * 2002-01-11 2005-06-30 アスファルマ リミテッド プラバスタチン医薬製剤及びその使用方法
EP1905431A1 (en) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
OA12777A (en) * 2002-02-14 2006-07-06 Ranbaxy Lab Ltd Formulations of atorvastatin stabilized with alkali metal additions.
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
EP2033631A3 (en) * 2002-09-03 2009-06-03 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
JP2006512359A (ja) * 2002-12-20 2006-04-13 ファイザー・プロダクツ・インク CETP阻害薬及びHMG−CoA還元酵素阻害薬を含有する剤形
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
US20080242725A1 (en) * 2004-03-01 2008-10-02 Janez Kerc Pharmaceutical Composition
KR100598326B1 (ko) 2004-04-10 2006-07-10 한미약품 주식회사 HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
WO2006008757A2 (en) * 2004-05-05 2006-01-26 Cadila Healthcare Limited Stabilized pharmaceutical compositions of pravastatin
BRPI0513082A (pt) * 2004-08-06 2008-04-22 Transform Pharmaceuticals Inc formulações de fenofibrato e métodos de tratamento relacionados
US7642287B2 (en) * 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
US20090208539A1 (en) 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1940391A4 (en) * 2005-08-05 2010-01-20 Orbus Pharma Inc STABILIZED PHARMACEUTICAL COMPOSITIONS WITH EXTENDED RELEASE WITH AN HMG COA REDUCTASE INHIBITOR
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
US20080038332A1 (en) * 2006-08-10 2008-02-14 Cai Gu Huang Stable pharmaceutical formulation comprising atorvastatin calcium
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
BG934U1 (bg) * 2006-12-14 2007-11-30 "Софарма" Ад Състав за твърда лекарствена форма, съдържащ правастатин
EP2170294A1 (en) * 2007-06-25 2010-04-07 Pharmathen S.A. Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof
GB0713707D0 (en) * 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
DE102007052071A1 (de) 2007-10-30 2009-05-07 Stada Arzneimittel Ag Stabilisiertes Atorvastatin
JPWO2011049122A1 (ja) * 2009-10-21 2013-03-14 第一三共株式会社 プラバスタチンナトリウム口腔内速崩壊錠及びその製造方法
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
TR201005326A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Çoklu dozaj formları.
WO2012002464A1 (ja) * 2010-06-30 2012-01-05 持田製薬株式会社 ω3脂肪酸の配合製剤
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
WO2012141160A1 (ja) * 2011-04-12 2012-10-18 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
WO2012153181A1 (en) * 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
WO2013072770A2 (en) 2011-11-15 2013-05-23 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
CN109044989A (zh) * 2018-10-09 2018-12-21 河南师范大学 一种阿托伐他汀钙胶囊制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US579837A (en) * 1897-03-30 Saw-sharpening machine
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
PL186907B1 (pl) * 1995-12-22 2004-03-31 Kowa Co Kompozycja farmaceutyczna stabilizowana czynnikiem zasadowym
FR2751316B1 (fr) * 1996-07-19 1998-08-28 Granger Maurice Appareil distributeur de bandes de papier ouate pour essuie-mains, papier toilette et similaire
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
SI1292293T1 (en) * 2000-06-09 2004-06-30 LEK farmacevtska dru�ba d.d. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
TW589178B (en) * 2003-02-21 2004-06-01 China Chemical & Pharmaceutica A novel industrial process to obtain pravastatin sodium of high purity

Also Published As

Publication number Publication date
EP1148872A1 (en) 2001-10-31
ES2299265T3 (es) 2008-05-16
ZA200103802B (en) 2002-06-10
BG105559A (en) 2001-12-29
SK8092001A3 (en) 2001-10-08
US20040072894A1 (en) 2004-04-15
WO2000035425A1 (en) 2000-06-22
CZ302562B6 (cs) 2011-07-13
YU35501A (sh) 2005-07-19
CA2348988C (en) 2009-07-21
JP2002532409A (ja) 2002-10-02
ATE380020T1 (de) 2007-12-15
CN1330538A (zh) 2002-01-09
AU6360899A (en) 2000-07-03
HUP0104258A2 (hu) 2002-03-28
KR100638307B1 (ko) 2006-10-25
IS5939A (is) 2001-05-15
DE69937691D1 (de) 2008-01-17
IL143759A0 (en) 2002-04-21
HUP0104258A3 (en) 2002-11-28
EP1148872B1 (en) 2007-12-05
DE69937691T2 (de) 2008-11-20
TR200101235T2 (tr) 2001-10-22
AU775946B2 (en) 2004-08-19
CA2348988A1 (en) 2000-06-22
US6680341B1 (en) 2004-01-20
US20090264497A1 (en) 2009-10-22
KR20010101105A (ko) 2001-11-14
RU2227019C2 (ru) 2004-04-20
SI1148872T1 (sl) 2008-04-30
EP1911445A3 (en) 2011-04-27
IL143759A (en) 2006-08-01
SI20109A (sl) 2000-06-30
EP1911445A2 (en) 2008-04-16
NZ511260A (en) 2004-01-30
PL347686A1 (en) 2002-04-22
CZ20011727A3 (cs) 2001-09-12
CN1198597C (zh) 2005-04-27

Similar Documents

Publication Publication Date Title
HRP20010325A2 (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
AU2000249434B2 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
AU2000249434A1 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
JP2004501121A5 (es)
SI21402A (sl) Obloženi delci in farmacevtske oblike
CA2692862C (en) Stable compositions
US6806290B2 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
SI21400A (sl) Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
EP1296672B1 (en) Stable pharmaceutical product and formulation

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20071005

Year of fee payment: 9

OBST Application withdrawn